8-K/A: EyePoint Completes Pivotal Phase 3 Enrollment for DURAVYU in Wet AMD, Anticipates Mid-2026 Topline Data

EyePoint Pharmaceuticals has successfully completed enrollment for both pivotal Phase 3 clinical trials, LUGANO and LUCIA, evaluating DURAVYU for wet age-related macular degeneration, ahead of schedule.

Summary

• EyePoint Pharmaceuticals has completed enrollment for its pivotal Phase 3 clinical trials, LUGANO and LUCIA, for DURAVYU in wet age-related macular degeneration (wet AMD).
• The LUCIA trial enrolled and randomized over 400 patients in seven months, contributing to over 800 patients enrolled across both LUGANO and LUCIA trials.
• This enrollment pace makes DURAVYU one of the fastest enrolling Phase 3 pivotal programs for wet AMD.
• An independent Data Safety Monitoring Committee (DSMC) confirmed no changes to the Phase 3 protocol and recommended continuation of the trial as planned.
• The safety profile observed in LUGANO and LUCIA is consistent with previous DURAVYU clinical trials, with no DURAVYU-related ocular or systemic serious adverse events observed across over 190 patients in four clinical trials.
• Topline 56-week data for the LUGANO trial is expected in mid-2026, with LUCIA data to follow closely thereafter.
• The Phase 3 pivotal program was developed in alignment with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).
• DURAVYU is designed as a sustained-delivery treatment, administered intravitreally every six months, aiming to reduce treatment burden compared to current standard-of-care anti-VEGF treatments dosed every two months.
• The company reported cash and cash equivalents of $318 million as of March 31, 2025, providing a cash runway into 2027, beyond the anticipated Phase 3 pivotal data in 2026.
• DURAVYU is also being evaluated for diabetic macular edema (DME), with positive Phase 2 VERONA trial results and a positive End-of-Phase 2 meeting with the FDA completed in July 2025, with pivotal program planning underway for 3Q 2025.

Sentiment

Score: 9

Explanation: The filing indicates significant positive progress with the completion of pivotal Phase 3 trial enrollment ahead of schedule, strong safety data, and positive regulatory alignment. This de-risks the clinical development pathway for a potentially transformative treatment in a large market, supported by a healthy cash position.

Positives

• Completed enrollment for both pivotal Phase 3 trials (LUGANO and LUCIA) for DURAVYU in wet AMD ahead of expectations.
• Rapid enrollment of over 800 patients across LUGANO and LUCIA trials, making it one of the fastest enrolling Phase 3 programs for wet AMD.
• Independent Data Safety Monitoring Committee (DSMC) recommended continuation of the program as planned, with no protocol changes.
• Favorable safety and tolerability profile observed, consistent with previous trials, with no DURAVYU-related ocular or systemic serious adverse events in over 190 patients.
• Phase 3 program design is aligned with FDA and EMA, enhancing potential for regulatory and commercial success.
• Strong efficacy and safety data from DAVIO 2 Phase 2 trial supports the Phase 3 pivotal program.
• DURAVYU offers a potential 6-month redosing schedule, significantly reducing treatment burden compared to current bi-monthly standard of care.
• Positive Phase 2 VERONA trial results for DME, demonstrating rapid and sustained improvement in vision and anatomy, supporting advancement to Phase 3.
• Completed a positive End-of-Phase 2 meeting with the FDA for the DME program.
• Cash and cash equivalents of $318 million as of March 31, 2025, provide a cash runway into 2027, past key data readouts.
• State-of-the-art cGMP manufacturing facility in Northbridge, MA, is operational and initiating registration batches to support future NDA filing and global commercial production.

Risks

• Timing, progress, and results of clinical development activities, including DURAVYU, are uncertain.
• Uncertainties and delays relating to communications with the U.S. Food and Drug Administration (FDA) and the ability to obtain regulatory approval for DURAVYU.
• Unanticipated costs and expenses could impact financial projections.
• Cash and cash equivalents may not be sufficient to support the operating plan for as long as anticipated.
• Results of clinical trials may not be predictive of future results, and interim/preliminary data are subject to further analysis and may change.
• Unexpected safety or efficacy data could be observed during clinical trials.
• Uncertainties related to the regulatory authorization or approval process and available development/regulatory pathways.
• Changes in the regulatory environment, including disruptions at the FDA due to workforce reduction or inadequate funding.
• Changes in U.S. and international trade policies.
• Changes in expected or existing competition.
• Success of current and future license agreements is not guaranteed.
• Dependence on contract research organizations and other outside vendors/service providers.
• Potential product liability claims.
• Impact of general business and economic conditions.
• Challenges in protecting intellectual property and avoiding infringement.
• Difficulty in retaining key personnel.
• Delays, interruptions, or failures in the manufacture and supply of product candidates.
• Availability of and the need for additional financing, and the ability to obtain additional funding.
• Uncertainties regarding the timing and results of the August 2022 subpoena from the U.S. Attorney's Office for the District of Massachusetts.
• Uncertainties regarding the FDA warning letter pertaining to the Watertown, MA manufacturing facility.

Future Outlook

EyePoint Pharmaceuticals anticipates topline 56-week data for the LUGANO trial in mid-2026, with LUCIA data to follow shortly thereafter. The company plans to advance its DME program to a Phase 3 pivotal program in 3Q 2025, following positive Phase 2 results and a successful End-of-Phase 2 meeting with the FDA. Management expresses optimism that DURAVYU has the potential to shift the treatment paradigm in wet AMD and DME, improving patient outcomes with its sustained-release profile.

Management Comments

• Jay S. Duker, M.D., President and Chief Executive Officer: "With enrollment now complete for our Phase 3 wet AMD program, well ahead of our expectations, we continue to demonstrate exceptional execution and our deep commitment to the retinal disease community. The industry-leading pace of our clinical program is a testament to the patient and physician enthusiasm for innovative, novel and more durable wet AMD treatments and DURAVYU's compelling and differentiated profile."
• Ramiro Ribeiro, M.D., Ph.D., Chief Medical Officer: "Similar to our LUGANO trial, LUCIA has exceeded enrollment timelines, underscoring our clinical development leadership and continued recognition by the retinal community of DURAVYU's best-in-class profile. We are proud of the clinical rigor and patient-centric approach underpinning our Phase 3 program, including our real-world design, which has now been approved by both the U.S. and European regulatory bodies, as well as use of an on-label standard of care comparator that resonates with physicians."
• Anat Loewenstein, M.D., MHA, Vice President Ambulatory Services, Head of Retina Tel Aviv Medical Center, President of European Society of Retina Specialists (EURetina) and member of EyePoint's Scientific Advisory Board: "The rapid enrollment of the LUCIA trial reflects its patient-centric design, DURAVYU's excellent safety profile, and EyePoint's ongoing engagement with the retinal community. Additionally, the 6-month redosing schedule being evaluated would enable greater clinical flexibility and improved compliance for patients, representing a potential paradigm shift for the treatment of wet AMD."

Industry Context

Wet age-related macular degeneration (wet AMD) is a leading cause of vision loss, requiring lifelong, continuous treatment. Current standard-of-care anti-VEGF treatments are typically dosed every two months, leading to significant patient and physician burden, potential noncompliance, and vision loss from missed visits. EyePoint's DURAVYU, a sustained-release tyrosine kinase inhibitor (TKI), aims to address this unmet need by offering a 6-month redosing schedule, potentially revolutionizing treatment by reducing injection frequency and improving patient compliance. Similarly, diabetic macular edema (DME) represents a large market with a significant unmet need for more durable treatments, which DURAVYU also targets.

Comparison to Industry Standards

• DURAVYU's proposed 6-month redosing schedule significantly extends the treatment interval compared to the current standard-of-care anti-VEGF treatments like aflibercept, which are typically dosed every two months in the U.S. under a treat-and-extend protocol.
• The Phase 3 pivotal program utilizes a non-inferiority design with an on-label aflibercept control, aligning with established FDA approval pathways and recognized industry best practices, similar to the last four FDA approvals in this space.
• DURAVYU's Durasert E technology is a next-generation bioerodible sustained-release insert, differentiating it from older non-erodible Durasert technologies (e.g., Vitrasert, Retisert, ILUVIEN, YUTIQ) by preventing free-floating drug particles and containing no PEG or PLGA.
• Vorolanib, the active ingredient in DURAVYU, is a differentiated and patent-protected tyrosine kinase inhibitor (TKI) that works intracellularly to inhibit all VEGF receptors and block PDGF, offering a novel mechanism of action compared to large molecule anti-VEGF treatments that typically target only one pathology of the disease.
• DURAVYU's safety profile, with no ocular or systemic serious adverse events observed in over 190 patients across four clinical trials, compares favorably to the known safety profiles of existing intravitreal injections.

Management Changes

Legal Proceedings

• Uncertainties regarding the timing and results of the August 2022 subpoena from the U.S. Attorney's Office for the District of Massachusetts.
• Uncertainties regarding the FDA warning letter pertaining to the Company's Watertown, MA manufacturing facility.

Stakeholder Impact

• **Shareholders:** Positive news regarding clinical trial progress and financial runway could increase investor confidence and potentially share price.
• **Patients:** Potential for a new, more durable treatment option for wet AMD and DME, significantly reducing treatment burden and improving compliance.
• **Physicians/Retinal Community:** A novel sustained-release therapy could offer greater clinical flexibility and resonate with practitioners seeking more effective and less frequent dosing options.
• **Employees:** Continued progress in clinical development and manufacturing supports job security and potential growth opportunities.
• **Regulatory Authorities:** The company's alignment with FDA and EMA guidelines and successful trial execution demonstrate commitment to regulatory standards.

Next Steps

• Anticipated topline 56-week data for the LUGANO trial in mid-2026.
• Topline data for the LUCIA trial to follow closely after LUGANO data.
• Planning for a Phase 3 pivotal program for DURAVYU in diabetic macular edema (DME) in 3Q 2025.
• Continued focus on bringing the first sustained-release TKI for wet AMD to market.
• Advancing the mission of delivering transformative treatment options for patients with serious retinal diseases.

Key Dates

Recommendation

The completion of pivotal Phase 3 enrollment for DURAVYU in wet AMD, ahead of schedule, is a significant de-risking event for EyePoint Pharmaceuticals. The positive safety profile observed to date, coupled with strong Phase 2 data and regulatory alignment, positions DURAVYU as a potential game-changer in a large and underserved market. The company's healthy cash position provides runway beyond key data readouts. While risks associated with clinical trials and regulatory approvals remain, the current progress suggests a high probability of success, making it an attractive investment for long-term growth.

Keywords

Wet AMD, Age-related macular degeneration, DURAVYU, EYP-1901, Vorolanib, Phase 3 clinical trials, LUGANO, LUCIA, Diabetic macular edema, DME, Durasert E, Sustained release, Tyrosine kinase inhibitor, TKI, Retinal diseases, Ophthalmology, Biopharmaceutical, Clinical development, FDA approval, Drug delivery